OUR SCIENCE

An investment
in the future

Female scientist looking into a microscope
Male scientist doing research in a lab

RESEARCH AND DEVELOPMENT

Developing novel treatments for CNS conditions

Throughout our history, Supernus Pharmaceuticals, Inc. has built a robust research and development program. We apply proprietary technologies to develop novel treatments that are designed to improve the lives of patients with CNS conditions.

This dedication to research has resulted in a successful track record of developing and launching novel products.

Our Science

From efficiency to efficacy

We are able to reduce the risks, costs, and time typically associated with pharmaceutical product development by focusing on drug compounds with established mechanisms of action. In addition, our technologies are designed to meet specific clinical efficacy needs with an improved safety and tolerability profile.

Microscope

Products utilizing our technologies

These technologies have been utilized to create ten marketed products, including Trokendi XR® and Oxtellar XR® (Supernus), Adderall XR®, Intuniv®, and Mydayis® (developed for Shire, now Takeda), and Orenitram® (developed for United Therapeutics Corporation).

CLINICAL TRIALS

Laying the foundation for new

therapies and innovations

Supernus Pharmaceuticals, Inc. is focused on developing products to meet the medical needs in the areas of neurology and psychiatry. To learn more about our current clinical trials for our product candidates, please visit www.ClinicalTrials.gov.

Explore Clinical Trials

A researcher working in a laboratory

PIPELINE

Innovative product candidates

Supernus is committed to the development of innovative product candidates in neurology and psychiatry. Below are our product candidates and their status in our pipeline.

Hypomobility in Parkinsons's disease

SPN-830

For the treatment of hypomobility in Parkinson’s disease

PRECLINICAL

 

PHASE 1

 

PHASE 2

 

PHASE 3

 

NDA FILING

 

NDA FILING

 
 
 
 
 

Treatment-resistant depression

SPN-820

For the treatment of treatment-resistant depression

PRECLINICAL

 

PHASE 1

 

PHASE 2

 

PHASE 3

 

NDA FILING

 

PHASE 1

 
 
 
 
 

Severe epilepsy

SPN-817

For the treatment of severe epilepsy

PRECLINICAL

 

PHASE 1

 

PHASE 2

 

PHASE 3

 

NDA FILING

 

PHASE 1

 
 
 
 
 

You may also be interested in Our Products